Chronic prostatitis: pathogenetic therapy

A pathogenetic approach means not simply "relieving symptoms," but specifically addressing the disease mechanisms that contribute to pain, dysuric (urinary) complaints, and decreased quality of life in a particular patient. Modern urology has long abandoned the idea of a single "universal" cause: in different men, the leading factors can be urodynamics (irritating and/or obstructive symptoms), local inflammation, muscular-fascial hypertonicity of the pelvic floor, psychosocial factors, and central sensitization, and sometimes a combination of these. This is why the phenotypic UPOINT/UPOINTS approach is now used and multimodal treatment plans are developed. [1]

Research by the MAPP network (a multicenter program of the US National Institutes of Health) has shown that some patients experience pain of a nociplastic nature (central sensitization), psychosocial factors (depression, catastrophizing) correlate with symptom severity, and widespread hypersensitivity outside the pelvic area is not uncommon. Hence, the logic: in parallel with local measures, it is essential to address the pain mechanisms of the nervous system, stress, and sleep. [2]

Table 1. Key pathogenetic links and what influences them

Pathogenetic link	What's happening	What are we aiming for in therapy?
Urodynamic disturbance (irritation/obstruction)	Overactive bladder, resistance to urine flow	Alpha blockers, 5-alpha reductase inhibitors for enlarged prostate, urinary control exercises
Local inflammation/immune response	IL-8 and other mediators, edema, pain	Short courses of anti-inflammatory drugs, proven herbal remedies (standardized pollen), and antibiotics in case of infection
Pelvic floor myofascial dysfunction	Spasm, trigger points, pain	Specialized pelvic floor physiotherapy, relaxation techniques
Central sensitization, stress	Increased pain, worsening of symptoms	Cognitive behavioral therapy, stress and sleep management, and catastrophizing
Sexual dysfunction and vascular factors	Erectile dysfunction, deterioration in quality of life	Daily tadalafil 5 mg, dealing with risk factors [3]

Phenotypic framework: UPOINT / UPOINTS - how to "catch" your profile

UPOINT is a system that breaks the syndrome down into domains: Urinary, Psychosocial, Organ-Specific (organ-specific prostate symptoms), Infection, Neurological/Systemic (neuro-systemic manifestations, somatization, central sensitization), and Tenderness (pelvic floor muscle pain). Adding Sexual (sexual function) forms the UPOINTS. The more domains that are active, the more severe the symptoms—and the more multi-layered the therapy should be. [4]

The 2024-2025 guidelines recommend personalizing treatment by domain, rather than prescribing the same treatment for everyone. For example, for severe irritant urinary symptoms, it is logical to try an alpha-blocker; for pelvic floor hypertonicity, immediately include myofascial physiotherapy; for severe pain catastrophizing, cognitive behavioral therapy; and for predominant pain, consider low-intensity shockwave therapy as a procedural option with a growing evidence base. [5]

Table 2. UPOINTS profile: examples of signs and first steps

Domain	Examples, at the reception	First targeted steps
Urinary	Urgency, increased frequency, weak stream	Alpha blocker; for prostate enlargement - 5-alpha-reductase inhibitor; fluid control
Psychosocial	Anxiety, depression, catastrophizing	Cognitive behavioral therapy, stress management techniques
Organ-specific	Prostate tenderness, inflammatory markers of secretion	Short courses of anti-inflammatory; standardized pollen
Infection	Confirmed bacterial cause	Etiotropic antibiotic course based on sensitivity (without “random courses”)
Neuro-systemic	Widespread pain, sleep disturbances	Pain management, sleep hygiene, psychological practices
Muscle tenderness	Pelvic floor spasm/pain	Myofascial release of the pelvic floor [6]

What the latest guides say

The 2024-2025 comprehensive guidelines of the European Association of Urology and the new 2025 guidelines of the American Urological Association agree on the key point: diagnosis and treatment are multimodal; there is no "one-size-fits-all" solution. Options include education and self-management, pelvic floor physiotherapy, targeted pharmacotherapy based on phenotype, and psychological methods; of the procedures, low-intensity shock wave therapy has the greatest research support in men. Antibiotics should be reserved for proven infection or in carefully selected patients at the very beginning of the disease, but not in a series of randomized trials. [7]

These documents specifically emphasize the value of quantitative outcome measures (National Institutes of Health Chronic Prostatitis Symptom Questionnaire, visual pain scale, voiding diaries) and 6- to 8-week checkpoints to decide whether to continue, modify, or change strategy. [8]

Table 3. Strong recommendations from the guidelines - what is often included in the plan

Block	What is almost always needed
Patient education and self-management	Explanation of the nature of pain, triggers, sleep/stress
Pelvic floor physiotherapy	Specialized myofascial techniques from a trained specialist
Phenotype-specific targeted drugs	Alpha-blocker for urinary symptoms; tadalafil for sexual dysfunction; short-term anti-inflammatory therapy for inflammatory phenotype
Procedures	Indications: low-intensity shock wave therapy
Psychological support	Cognitive behavioral therapy, working with catastrophizing [9]

Pharmacotherapy

Alpha-blockers. Data are mixed: a large study with alfuzosin in previously treated men showed no benefit, but targeted reviews and a network meta-analysis note a benefit in some patients, particularly those with severe urinary symptoms and a short disease duration. This is a typical "phenotype-dependent" option. [10]

Antibiotics. Randomized trials of 6-week courses of ciprofloxacin and levofloxacin for persistent nonbacterial forms have shown no benefit over placebo. Antibiotics are appropriate for confirmed infection or in a small group of recent patients with convincing evidence of an inflammatory phenotype; "repeat empirical courses" are a poor strategy. [11]

5-alpha-reductase inhibitors. Pilot studies suggest benefit in some men with an inflammatory phenotype, but this drug is not standard treatment for monotherapy outside the context of an enlarged prostate. Consider this if the prostate is enlarged and there are obstructive symptoms. [12]

Drugs that affect the vascular component and erectile function. Daily tadalafil 5 mg improved total symptom scores and quality of life in men with chronic prostatitis/pelvic pain in a randomized trial; the American Urological Association guidelines note it as the most studied of the phosphodiesterase-5 inhibitor class. It is particularly useful when combined with erectile dysfunction. [13]

Nonsteroidal anti-inflammatory drugs and other anti-inflammatory drugs. Short courses are helpful for acute pain and inflammation; systematic reviews show modest but consistent benefit. [14]

Neuromodulators (pregabalin, etc.). A large multicenter randomized trial of pregabalin failed to confirm its superiority over placebo; there are few high-quality randomized trials for tricyclic antidepressants and selective serotonin reuptake inhibitors in men. The decision is individualized, with an honest discussion of expectations and side effects. [15]

Evidence-based herbal remedies. Standardized pollen extract (Cernilton) showed superiority over placebo in a randomized trial in men with an inflammatory phenotype; quercetin also improved symptoms in a double-blind study. These remedies are options for supplementing the baseline regimen in selected patients. [16]

Table 4. Pharmacotherapy: where the data is “for” and where “against”

Class	What the database shows	Who usually needs this?
Alpha blockers	The effect is variable; better with severe urinary symptoms and short duration	Patients with irritant/obstructive complaints without infection
Antibiotics	RCTs for persistent nonbacterial forms are no better than placebo	Only in cases of proven infection or a small number of early cases
5-alpha-reductase inhibitors	Pilot signals of benefit; not standard outside of enlarged prostate	For prostate enlargement and obstruction
Tadalafil	Improvement of symptoms and quality of life	For a combination of pelvic pain and sexual dysfunction
Nonsteroidal anti-inflammatory drugs	Moderate benefit in exacerbations	Inflammatory phenotype, short courses
Pollen, quercetin	Plus symptoms in RCTs in some patients	Inflammatory phenotype as an additive [17]

Non-pharmacological and procedural methods: the "skeleton" of the pathogenetic plan

Pelvic floor physiotherapy (myofascial). Randomized multicenter trials in patients with urological chronic pelvic pain (including men) have demonstrated a clinically significant benefit of specialized myofascial therapy over standard relaxation massage. This is a key module for patients with pelvic floor muscle pain. [18]

Cognitive behavioral therapy and pain education. The 2025 guidelines and current reviews support the inclusion of psychological methods for the nociplastic component of pain; interventions targeting catastrophizing have been shown to be associated with improved outcomes. [19]

Low-intensity shock wave therapy. By 2023–2024, randomized trials and reviews on pain reduction and quality of life improvement in men with chronic nonbacterial prostatitis had accumulated; the method was mentioned in guidelines as a procedural option in the plan. [20]

Acupuncture. There are systematic reviews and meta-analyses with positive results, but the quality of some studies is limited; the method is acceptable as an adjunct in a center with experienced specialists. [21]

Table 5. Non-pharmacological and procedural modules

Method	What does it give?	When it is especially appropriate
Myofascial physiotherapy of the pelvic floor	Pain reduction, muscle relaxation	Positive domain of "tenderness"
Cognitive behavioral therapy	Reduced catastrophizing, improved pain tolerance	Positive psychosocial domain, sleep disorders
Low intensity shock wave therapy	Reduced pain, improved quality of life	Persistent pain, desire for a procedural option
Acupuncture	Additional symptom reduction	As part of a multimodal plan [22]

What is definitely not a "pathogenetic standard"

Multiple "empirical" antibiotics without signs of infection; "mono-courses" without phenotype assessment; aggressive intraprostatic injections outside of research; promises of a "once-and-for-all cure" with a single device. All of this contradicts the spirit of modern recommendations and often worsens the prognosis due to patient burnout and persistent symptoms. [23]

How to Create a 12-Week Personalized Plan: The Honest Way

1. UPOINTS phenotyping (including pelvic floor palpation, basic urodynamics, ruling out infection and red flags).
2. Clear measurable goals (reduce pain by 2-3 points on a visual scale, reduce nighttime awakenings to 0-1, improve quality of life according to a symptom questionnaire).
3. The basis for everything: pain management, sleep and stress hygiene, myofascial physiotherapy (if there is muscle soreness), targeted medications by domain.
4. Indications: Low-intensity shockwave therapy; additional methods should be discussed honestly, with reference to the database.
5. Checkpoint 6-8 weeks: if the response is insufficient, modify: strengthen the psychological block, change pharmacotherapy, reconsider the hypothesis of the mechanism. [24]

Table 6. Example of a plan with “exit points”

Element	What do we measure?	Continuation criteria for 6-8 weeks
Pelvic floor physiotherapy	Pain (0-10), muscle sensitivity	-2 or more points of pain or a clear decrease in pain
Alpha blocker/tadalafil	Frequency/urgency, quality of life	Clinically significant improvement according to the questionnaire
Anti-inflammatory "ladder"	Pain, feeling of "inflammation"	Clear dynamics without side effects
Procedures (shock wave)	Pain, quality of life	Significant improvement, good tolerability [25]

Briefly about controversial and further discussed areas

• Neuromodulators (eg, pregabalin): large RCT negative; possible occasional use for concomitant neurological pain syndromes, but not as a “panacea.” [26]
• 5-alpha-reductase inhibitors: reserved for men with enlarged prostates and obstructive symptoms (as a “double whammy” for the mechanism). [27]
• Phytotherapy: standardized pollen and quercetin are options in selected patients; saw palmetto has not been shown to be effective for urinary symptoms in large studies.[28]

Table 7. “Myths and facts” of pathogenetic treatment

Statement	Reality
"One right antibiotic is all it takes, and everything will be fine."	Without infection, antibiotics are no better than placebo and create problems in the future. [29]
"If an alpha-blocker doesn't help within two weeks, it's not working."	Assess after 4-8 weeks, and only in those whose symptoms are phenotypically sensitive to it. [30]
Pregabalin is a universal solution.	RCT negative; use sparingly and with caution. [31]
"One device will solve everything"	The procedures are part of the plan; without working with muscles, sleep and stress, the effect is weaker. [32]